Clinical presentation and management of drug-induced agranulocytosis

Expert Review of Hematology

Volumn 4, Issue 2, 2011, Pages 143-151

  Andrès, Emmanuel ^a   Zimmer, Jacques ^b   Mecili, Mustapha ^a   Weitten, Thierry ^a   Alt, Martine ^c   Maloisel, Frédéric ^d  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c Center of Pharmacovigilance of Alsace   (France)

^d Department of Hematology   (France)

Author keywords

agranulocytosis; hematopoietic growth factor; idiosyncratic drug induced agranulocytosis; infections; neutropenia

Indexed keywords

ACETAZOLAMIDE; ACETYLCYSTEINE; ALLOPURINOL; AMINOGLUTETHIMIDE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTITHYROID AGENT; ARSENIC DERIVATIVE; BEZAFIBRATE; BROMPHENIRAMINE; CARDIOVASCULAR AGENT; CHLORPHENIRAMINE; CIMETIDINE; COLCHICINE; DAPSONE; DEFERIPRONE; DOBESILATE CALCIUM; FAMOTIDINE; FLUTAMIDE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; HYPNOTIC SEDATIVE AGENT; MESALAZINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; UNINDEXED DRUG;

AGE DISTRIBUTION; AGRANULOCYTOSIS; ANTIBIOTIC THERAPY; ARTICLE; DEEP TISSUE INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEVER; GENETIC POLYMORPHISM; HOSPITAL PATIENT; HUMAN; IDIOSYNCRATIC DRUG INDUCED AGRANULOCYTOSIS; INFECTION; KIDNEY FAILURE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METABOLIC DISORDER; MORTALITY; NEUTROPHIL COUNT; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SEPTICEMIA; SKIN INFECTION; SORE THROAT; TONSILLITIS;

AGE FACTORS; AGRANULOCYTOSIS; ANTI-BACTERIAL AGENTS; ANTITHYROID AGENTS; DIAGNOSIS, DIFFERENTIAL; FIBRINOLYTIC AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE COUNT; NEUTROPHILS; PNEUMONIA; RENAL INSUFFICIENCY; RISK FACTORS; SEPSIS;

EID: 79955050820     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.11.12     Document Type: Article

References (37)

1. Schultz W. Ueber eigenartige halserkrankungen. Dtsch Med. Wochenschr. 48, 1495-1496 (1922).
2. Bénichou C. Adverse Drug Reactions. A Practical Guide to Diagnosis and Management. WJ Wiley, NY, USA (1994).
3. Andrès E, Dali-Youcef N, Serraj K, Zimmer J. Recognition and management of drug-induced blood-cytopenias: the example of idiosyncratic drug-induced thrombocytopenia. Expert Opin. Drug Saf. 8, 183-190 (2009).
4. Andersohn F, Konzen C, Garbe E. Non-chemotherapy drug-induced agranulocytosis: a systematic review of case reports. Ann. Intern. Med. 146, 657-665 (2007). (Pubitemid 351650522)
5. Andersohn F, Bronder E, Klimpel A, Garbe E. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am. J. Hematol. 77, 316-318 (2004). (Pubitemid 39430715)
6. Bénichou C, Solal-Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv. Rev. Fr. Hematol. 33, 257-262 (1993).
7. Van der Klauw MM, Goudsmit R, Halie MR et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch. Intern. Med. 159, 369-374 (1999). (Pubitemid 29091625)
8. Van Staa TP, Boulton F, Cooper C, Hagenbeek A, Inskip H, Leufkens HG. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am. J.Hematol. 72, 248-254 (2003). (Pubitemid 36383975)
9. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch. Intern. Med. 165, 869-874 (2005). (Pubitemid 40563233)
10. Theophile H, Begaud B, Martin K, Laporte JR, Capella D. Incidence of agranulocytosis in Southwest France. Eur. J. Epidemiol. 19, 563-565 (2004). (Pubitemid 39005418)
11. Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M. Descriptive epidemiology of agranulocytosis. Arch. Intern. Med. 152, 1475-1480 (1992).
12. Andrès E, Maloisel F, Kurtz JE et al. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur. J. Intern. Med. 13, 324-328 (2002). (Pubitemid 34812343)
13. Patton WN, Duffull SB. Idiosyncratic drug-induced haematological abnormalities: incidence, pathogenosis, management and avoidance. Drug Saf. 11, 445-462 (1994).
14. Paitel JF, Stockemer V, Dorvaux V, Witz F, Guerci A, Lederlin P. [Drug-induced agranulocytosis. Clinical study about 30 patients and etiological evolution between 2 decades]. Rev. Med. Interne 16, 495-499 (1995).
15. Vial T, Pofilet C, Pham E, Payen C, Evreux JC. [Acute drug-induced agranulocytosis: experience of the Regional Center of Pharmacovigilance of Lyon over 7 years]. Therapie 51, 508-515 (1996).
16. Shapiro S, Issaragrisil S, Kaufman DW et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am. J. Trop. Med. Hyg. 60, 573-577 (1999). (Pubitemid 29233112)
17. Van der Klauw MM, Wilson JH, Stricker BH. Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974-1994).Am. J. Hematol. 57, 206-211 (1998). (Pubitemid 28139236)
18. Kaufman DW, Kelly JP, Jurgelon JM et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur. J. Haematol. 60(Suppl.), 23-30 (1996).
19. Kelly JP, Kaufman DW, Shapiro S. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study. Clin. Pharmacol. Ther. 49, 330-341 (1991).
20. Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish caucasian sample. Arch. Gen. Psychiatry 58, 93-94 (2001). (Pubitemid 32057770)
21. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr. Opin. Hematol. 15, 15-21 (2008). (Pubitemid 350191024)
22. Julia A, Olona M, Bueno J et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br. J. Hematol. 79, 366-372 (1991).
23. Maloisel F, Andrès E, Kaltenbach G, Noel E, Martin-Hunyadi C, Dufour P. Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis. A study of 91 patients from a single center. Presse Med. 33, 1164-1168 (2004). (Pubitemid 39371586)
24. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-inducedagranulocytosis. The usefulness of routine white blood cell count monitoring. Arch. Intern. Med. 150, 621-624 (1990). (Pubitemid 20122017)
25. Tajiri J. Antithyroid drug-induced agranulocytosis: special reference to normal white cell count agranulocytosis. Thyroid 14, 459-462 (2004). (Pubitemid 38868766)
26. Andrès E, Noel E, Kurtz JE, Henoun Loukili N, Kaltenbach G, Maloisel F. Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients. Drugs Aging 21, 427-435 (2004). (Pubitemid 38736888)
27. Weitten T, Alt M, Decker N, Andrès E; Réseau National des Centres de Pharmacovigilance. [Antithyroid-drug induced agranulocytosis: epidemiological and clinical data about 203 cases included in the France national data base of pharmacovigilance]. Rev. Med. Interne 30(Suppl. 4), S347-S348 (2009).
28. Carey PJ. Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26, 691-706 (2003). (Pubitemid 36976131)
29. Andrès E, Kurtz JE, Martin-Hunyadi C et al. Non-chemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am. J. Med. 112, 460-464 (2002). (Pubitemid 34450706)
30. Andrès E, Kurtz JE, Perrin AE, Dufour P, Schlienger JL, Maloisel F. The use of haematopoietic growth factors in anti-thyroid-related drug-induced agranulocytosis: a report of 20 patients. QJ Med. 94, 423-428 (2001).
31. Sprikkelman A, de Wolf JTM, Vellenga E. Application of haematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 8, 2031-2036 (1994).
32. Beauchesne MF, Shalansky SJ. Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 19, 299-305 (1999). (Pubitemid 29118171)
33. Ibáñez L, Sabaté M, Ballarín E et al. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. Pharmacoepidemiol. Drug Saf. 17(3), 224-228 (2008). (Pubitemid 351404033)
34. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from anti-thyroid drug-induced agranulocytosis: a prospective study. Thyroid 9, 29-31 (1999). (Pubitemid 29081147)
35. Andrès E, Noel E, Maloisel F. Long-term outcome of patients treated with hematopoietic growth factors for idiosyncratic drug-induced agranulocytosis. Am. J. Med. 116, 354 (2004). (Pubitemid 38230298)
36. Bhatt V, Saleem A. Drug-induced neutropenia: pathophysiology, clinical features, and management. Ann. Clin. Lab. Sci. 34, 131-137 (2004). (Pubitemid 38685904)
37. Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors G-CSF and GM-CSF in the management of drug-induced agranulocytosis. Br. J. Haematol. 150, 3-8 (2010).